| Inositol hexaphosphate-loaded red blood cells prevent in vitro sickling. | |
| | |
MedLine Citation:
|
PMID: 20456710 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Hypoxia is a major cause of painful vaso-occlusive crisis in sickle cell disease (SCD). Simple transfusion and red blood cell (RBC) exchange are commonly used as preventive therapies whose aim is to dilute hemoglobin (Hb)S-containing RBCs (SS-RBCs) with normal RBCs (AA-RBCs) to prevent sickling. We hypothesized that the effectiveness of transfusion could be improved by the encapsulation of inositol hexaphosphate (IHP), an allosteric Hb effector, in transfused AA-RBCs. Indeed, apart from their diluting effect on SS-RBCs, IHP-loaded RBCs (IHP-RBCs) with increased oxygen release capacity could palliate in vivo oxygen deprivation and reduce sickling. STUDY DESIGN AND METHODS: The study was designed to investigate the therapeutic effect of IHP-RBCs transfusion on in vitro sickling of SS-RBCs collected from 20 SCD patients. Patients' RBCs were diluted with various proportions of IHP-RBCs or AA-RBCs (processed or stored RBCs as controls). Resulting suspensions were subjected to deoxygenation followed by partial reoxygenation at 5% oxygen. Sickling was evaluated by microscopy. RESULTS: Stored RBCs (50% dose) used to mimic simple transfusion exhibited a poor antisickling effect (5.6%) and a low response rate (65%). In contrast, IHP-RBCs treatment was seven times more effective resulting in 35% of sickling reduction and a 94% response rate. Sickling was inhibited in a dose-dependent manner: 9.9, 25.1, and 35.0% for IHP-RBCs in percentages of 10, 30, and 50%, respectively. CONCLUSION: Our results indicate that IHP-RBCs prevent in vitro sickling and suggest that it could improve conventional transfusion therapy in terms of transfused volume, frequency, and efficacy. |
| | |
Authors:
|
Vanessa Bourgeaux; Olivier Hequet; Yannick Campion; Gaëlle Delcambre; Anne-Marie Chevrier; Dominique Rigal; Yann Godfrin |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-10-04 |
Journal Detail:
|
Title: Transfusion Volume: 50 ISSN: 1537-2995 ISO Abbreviation: Transfusion Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-11-02 Completed Date: 2010-11-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0417360 Medline TA: Transfusion Country: United States |
Other Details:
|
Languages: eng Pagination: 2176-84 Citation Subset: IM |
Copyright Information:
|
© 2010 American Association of Blood Banks. |
Affiliation:
|
ERYtech Pharma and EFS Rhône Alpes, Lyon, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Anemia, Sickle Cell / drug therapy*, therapy* Erythrocytes / chemistry*, cytology* Female Humans Male Phytic Acid / chemistry*, therapeutic use Young Adult |
| Chemical | |
Reg. No./Substance:
|
83-86-3/Phytic Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of storage duration and volume on the quality of leukoreduced apheresis-derived platelets: i...
Next Document: A solution to the problem of studying blood donor-related risk factors when patients have received m...